Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.33
BRLI's Cash to Debt is ranked higher than
51% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. BRLI: 0.33 )
BRLI' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 0.33

Equity to Asset 0.65
BRLI's Equity to Asset is ranked higher than
72% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. BRLI: 0.65 )
BRLI' s 10-Year Equity to Asset Range
Min: 0.33   Max: 0.73
Current: 0.65

0.33
0.73
Interest Coverage 51.04
BRLI's Interest Coverage is ranked higher than
60% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 116.56 vs. BRLI: 51.04 )
BRLI' s 10-Year Interest Coverage Range
Min: 0.85   Max: 52.32
Current: 51.04

0.85
52.32
F-Score: 3
Z-Score: 6.41
M-Score: -1.92
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 9.17
BRLI's Operating margin (%) is ranked higher than
82% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. BRLI: 9.17 )
BRLI' s 10-Year Operating margin (%) Range
Min: -6.49   Max: 12.39
Current: 9.17

-6.49
12.39
Net-margin (%) 4.97
BRLI's Net-margin (%) is ranked higher than
77% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.31 vs. BRLI: 4.97 )
BRLI' s 10-Year Net-margin (%) Range
Min: -9.28   Max: 8.27
Current: 4.97

-9.28
8.27
ROE (%) 14.21
BRLI's ROE (%) is ranked higher than
85% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.65 vs. BRLI: 14.21 )
BRLI' s 10-Year ROE (%) Range
Min: -35.97   Max: 24.15
Current: 14.21

-35.97
24.15
ROA (%) 9.23
BRLI's ROA (%) is ranked higher than
88% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.89 vs. BRLI: 9.23 )
BRLI' s 10-Year ROA (%) Range
Min: -13.68   Max: 14.14
Current: 9.23

-13.68
14.14
ROC (Joel Greenblatt) (%) 29.08
BRLI's ROC (Joel Greenblatt) (%) is ranked higher than
84% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.61 vs. BRLI: 29.08 )
BRLI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -19.55   Max: 43.5
Current: 29.08

-19.55
43.5
Revenue Growth (%) 16.30
BRLI's Revenue Growth (%) is ranked higher than
91% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. BRLI: 16.30 )
BRLI' s 10-Year Revenue Growth (%) Range
Min: 1.3   Max: 22.4
Current: 16.3

1.3
22.4
EBITDA Growth (%) 19.60
BRLI's EBITDA Growth (%) is ranked higher than
90% of the 125 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.50 vs. BRLI: 19.60 )
BRLI' s 10-Year EBITDA Growth (%) Range
Min: -18.1   Max: 37.3
Current: 19.6

-18.1
37.3
EPS Growth (%) 20.60
BRLI's EPS Growth (%) is ranked higher than
89% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. BRLI: 20.60 )
BRLI' s 10-Year EPS Growth (%) Range
Min: -61.8   Max: 196.2
Current: 20.6

-61.8
196.2
» BRLI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

BRLI Guru Trades in Q3 2013

Paul Tudor Jones 18,900 sh (+5%)
Mario Gabelli 55,700 sh (+2.77%)
Jean-Marie Eveillard 12,000 sh (unchged)
Chase Coleman 720,000 sh (unchged)
John Hussman Sold Out
Joel Greenblatt 47,324 sh (-15.9%)
Chuck Royce 115,600 sh (-35.06%)
» More
Q4 2013

BRLI Guru Trades in Q4 2013

Paul Tudor Jones 31,198 sh (+65.07%)
Mario Gabelli 56,400 sh (+1.26%)
Chuck Royce 115,600 sh (unchged)
Chase Coleman 720,000 sh (unchged)
Jean-Marie Eveillard 12,000 sh (unchged)
Joel Greenblatt 30,507 sh (-35.54%)
» More
Q1 2014

BRLI Guru Trades in Q1 2014

Steven Cohen 21,122 sh (New)
Manning & Napier Advisors, Inc 447,026 sh (New)
Chuck Royce 258,934 sh (+123.99%)
Mario Gabelli 58,700 sh (+4.08%)
Chase Coleman 720,000 sh (unchged)
Jean-Marie Eveillard 12,000 sh (unchged)
Joel Greenblatt Sold Out
Paul Tudor Jones 15,400 sh (-50.64%)
» More
Q2 2014

BRLI Guru Trades in Q2 2014

John Hussman 50,000 sh (New)
Paul Tudor Jones 19,717 sh (+28.03%)
Chuck Royce 304,334 sh (+17.53%)
Steven Cohen 8,000 sh (unchged)
Chase Coleman 720,000 sh (unchged)
Jean-Marie Eveillard Sold Out
Manning & Napier Advisors, Inc Sold Out
Mario Gabelli 58,500 sh (-0.34%)
» More
» Details

Insider Trades

Latest Guru Trades with BRLI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2014-06-30 New Buy0.12%$24.74 - $32.74 $ 29.256%50000
Jean-Marie Eveillard 2014-06-30 Sold Out $24.74 - $32.74 $ 29.256%0
Joel Greenblatt 2014-03-31 Sold Out 0.02%$24.39 - $28.26 $ 29.2512%0
Joel Greenblatt 2013-12-31 Reduce -35.54%0.02%$25.17 - $37.73 $ 29.25-5%30507
John Hussman 2013-09-30 Sold Out 0.15%$25.78 - $30.14 $ 29.255%0
Joel Greenblatt 2013-06-30 Reduce -46.02%0.06%$23.58 - $31.9 $ 29.256%56271
John Hussman 2013-03-31 New Buy0.11%$24.91 - $31.05 $ 29.256%116000
Joel Greenblatt 2013-03-31 Add 21.81%0.03%$24.91 - $31.05 $ 29.256%104240
Joel Greenblatt 2012-12-31 Add 48.67%0.05%$24.68 - $32.42 $ 29.252%85579
Joel Greenblatt 2012-03-31 New Buy0.12%$16.27 - $23.76 $ 29.2555%57406
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Bio-Reference Laboratories Inc

Medical Diagnostic Labs Facing Medicare Headwinds
Currently medical diagnostic lab stocks are trading at near historical lows for price-to-sales (P/S). At first sight these companies might look like bargains, but lower p/s ratios might be the new normal for these companies. I have taken a closer look at Lab Corp of America (LH), Quest Diagnostics (DGX), and Bio-Reference Labs (BRLI). Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 20.50
BRLI's P/E(ttm) is ranked higher than
86% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BRLI: 20.50 )
BRLI' s 10-Year P/E(ttm) Range
Min: 9.34   Max: 39.85
Current: 20.5

9.34
39.85
P/B 2.70
BRLI's P/B is ranked higher than
71% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.00 vs. BRLI: 2.70 )
BRLI' s 10-Year P/B Range
Min: 1.77   Max: 7.83
Current: 2.7

1.77
7.83
P/S 1.00
BRLI's P/S is ranked higher than
89% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.90 vs. BRLI: 1.00 )
BRLI' s 10-Year P/S Range
Min: 0.61   Max: 2.44
Current: 1

0.61
2.44
EV-to-EBIT 11.48
BRLI's EV-to-EBIT is ranked higher than
92% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BRLI: 11.48 )
BRLI' s 10-Year EV-to-EBIT Range
Min: 5.9   Max: 28.6
Current: 11.48

5.9
28.6
PEG 0.99
BRLI's PEG is ranked higher than
97% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BRLI: 0.99 )
BRLI' s 10-Year PEG Range
Min: 0.36   Max: 1.33
Current: 0.99

0.36
1.33
Shiller P/E 22.70
BRLI's Shiller P/E is ranked higher than
93% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BRLI: 22.70 )
BRLI' s 10-Year Shiller P/E Range
Min: 15.42   Max: 270
Current: 22.7

15.42
270
Current Ratio 2.25
BRLI's Current Ratio is ranked higher than
65% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. BRLI: 2.25 )
BRLI' s 10-Year Current Ratio Range
Min: 1.11   Max: 3.11
Current: 2.25

1.11
3.11
Quick Ratio 2.12
BRLI's Quick Ratio is ranked higher than
68% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.29 vs. BRLI: 2.12 )
BRLI' s 10-Year Quick Ratio Range
Min: 1.08   Max: 2.9
Current: 2.12

1.08
2.9

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 15.11
BRLI's Price/Net Current Asset Value is ranked higher than
70% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BRLI: 15.11 )
BRLI' s 10-Year Price/Net Current Asset Value Range
Min: 11.78   Max: 83.13
Current: 15.11

11.78
83.13
Price/Tangible Book 3.21
BRLI's Price/Tangible Book is ranked higher than
76% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.10 vs. BRLI: 3.21 )
BRLI' s 10-Year Price/Tangible Book Range
Min: 0.68   Max: 9
Current: 3.21

0.68
9
Price/DCF (Projected) 2.12
BRLI's Price/DCF (Projected) is ranked higher than
77% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BRLI: 2.12 )
BRLI' s 10-Year Price/DCF (Projected) Range
Min: 1.86   Max: 36.33
Current: 2.12

1.86
36.33
Price/Median PS Value 0.78
BRLI's Price/Median PS Value is ranked higher than
82% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. BRLI: 0.78 )
BRLI' s 10-Year Price/Median PS Value Range
Min: 0.11   Max: 1.76
Current: 0.78

0.11
1.76
Price/Peter Lynch Fair Value 1.20
BRLI's Price/Peter Lynch Fair Value is ranked higher than
95% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BRLI: 1.20 )
BRLI' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.61   Max: 1.4
Current: 1.2

0.61
1.4
Price/Graham Number 1.70
BRLI's Price/Graham Number is ranked higher than
88% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BRLI: 1.70 )
BRLI' s 10-Year Price/Graham Number Range
Min: 0.3   Max: 5.26
Current: 1.7

0.3
5.26
Earnings Yield (Greenblatt) 8.70
BRLI's Earnings Yield (Greenblatt) is ranked higher than
80% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.90 vs. BRLI: 8.70 )
BRLI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.5   Max: 17
Current: 8.7

3.5
17
Forward Rate of Return (Yacktman) 18.08
BRLI's Forward Rate of Return (Yacktman) is ranked higher than
91% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.68 vs. BRLI: 18.08 )
BRLI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1   Max: 34.9
Current: 18.08

-1
34.9

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, DGX, LIFE, ENZ, IDXX » details
Traded in other countries:BFR.Germany
Bio-Reference Laboratories, Inc., is a New Jersey corporation incorporated on December 24, 1981. It offers testing, information and related services to physician offices, clinics, hospitals, employers and governmental units. It offers a comprehensive list of laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring and treatment of diseases. It mainly focuses on esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional health care. The Company currently process approximately 6.7 million laboratory test requisitions each year. It has a network of 98 patient service centers located in the Northeast (mainly in New York metropolitan super-regional area) for collection of patient specimens. It currently conducts business in most New York State counties, as well as in most of New Jersey and Maryland as well as some parts of Pennsylvania, Delaware and Connecticut. It mainly offers laboratory services to physician offices in these areas with an infrastructure that includes a comprehensive logistical department, extensive phlebotomy services and phlebotomy draw stations scattered around its geographic area. The Company also operates a web-based connectivity portal solution for laboratories and physicians through its CareEvolve subsidiary. It uses this portal itself to provide laboratory ordering and results as well as connectivity to its physician customers. It also markets and licenses this connectivity solution to other laboratories throughout the country. The Company competes with three types of providers in a highly fragmented and competitive industry: hospital laboratories, physician-office laboratories and other independent clinical laboratories. Its major competitors in the New York metropolitan area are Quest Diagnostics and Laboratory Corporation of America. The Company is subject to federal and state laws and regulations regarding the protection of the environment, the health and safety of employees, and the handling, transportation and disposal of medical specimens, and infectious and hazardous wastes.
» More Articles for BRLI

Headlines

Articles On GuruFocus.com
Small cap high short interest (Predictability = 5), Part 1 Oct 16 2014 
Why I Like These Two Health Care Stocks Aug 29 2014 
LabCorp: A Leading Independent Diagnostic Laboratory Aug 22 2014 
DaVita Seems to be a High-Growth Company Aug 20 2014 
Small-Cap Consensus Picks By The Investing Gurus Jul 25 2014 
4 Attractive Small-Cap Growth + Value Stocks You Have Never Heard Of Apr 16 2014 
Medical Diagnostic Labs Facing Medicare Headwinds Mar 25 2014 
Historical Short Interest Of Stocks – New Feature Announcement Jan 17 2014 
New Feature Announcement: Stocks With The Highest Short Interest Dec 12 2013 
comment on BRLI May 11 2013 

More From Other Websites
Nasdaq stocks posting largest percentage increases Oct 24 2014
BIO REFERENCE LABORATORIES INC Financials Sep 10 2014
BIO REFERENCE LABORATORIES INC Files SEC form 10-Q, Quarterly Report Sep 04 2014
Bio-Reference Laboratories (BRLI) Crumbles: Stock Tumbles by 9.2% Aug 29 2014
Bio-Reference Laboratories Inc Earnings Call scheduled for 10:30 am ET today Aug 27 2014
BIO REFERENCE LABORATORIES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 27 2014
BioReference Laboratories, Inc. Reports Record Quarterly Revenues and Patient Volumes for Third... Aug 27 2014
Q3 2014 Bio-Reference Laboratories Inc Earnings Release - Before Market Open Aug 27 2014
Lessons To Take From Health Care's Strong 2014 And What To Buy Now Aug 25 2014
BioReference Laboratories, Inc. Announces Earnings Date for Third Quarter Fiscal Year 2014 Aug 20 2014
Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference... Aug 18 2014
Myriad Genetics Guidance Disappoints, Q4 Edges Views Aug 12 2014
Myriad Genetics' Earnings Face 'Angelina Jolie' Comps Aug 11 2014
BIO REFERENCE LABORATORIES INC Files SEC form 8-K/A, Submission of Matters to a Vote of Security... Jul 24 2014
BIO REFERENCE LABORATORIES INC Files SEC form 8-K, Submission of Matters to a Vote of Security... Jul 17 2014
Investors Are Shorting Bio-Reference Laboratories (BRLI) Stock: Is A Short Cover Coming? Jul 09 2014
Antares Pharma (ATRS) Crumbles: Stock Falls by 8.3% Jun 25 2014
Performance Of The Best Small Companies Updated Jun 09 2014
Bio-Reference Laboratories - Solid Growth, Fair Valuation, Long-Term Opportunity Jun 06 2014
Perilous Reversal Watch: Bio-Reference Laboratories (BRLI) Jun 06 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK